Hutchin Hill Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Hutchin Hill Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-29,900	Closed	-$607K	–	837
2017 Q3	$607K	Buy	+29,900	New	+$572K	0.02%	480
2017 Q1	–	Sell	-42,700	Closed	-$566K	–	1146
2016 Q4	$566K	Buy	+42,700	New	+$730K	0.02%	571
2016 Q3	–	Sell	-43,300	Closed	-$1.25M	–	783
2016 Q2	$1.25M	Buy	43,300 +21,400	+98%	+$698K	0.04%	270
2016 Q1	$701K	Buy	+21,900	New	+$770K	0.02%	488
2015 Q1	–	Sell	-16,000	Closed	-$507K	–	860
2014 Q4	$507K	Buy	+16,000	New	+$468K	0.02%	447
2013 Q4	–	Sell	-29,400	Closed	-$602K	–	690
2013 Q3	$602K	Sell	29,400 -8,300	-22%	-$171K	0.05%	294
2013 Q2	$752K	Buy	+37,700	New	+$669K	0.08%	212

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hutchin Hill Capital's IPXL Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 29,900 shares — an estimated $607K sold.

Hutchin Hill Capital first reported a position in IPXL in Q2 2013 and held it in 7 quarters. The position peaked at $1.25M in Q2 2016. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Hutchin Hill Capital reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 29,900 Impax Laboratories, Inc. shares in Q4 2017, an estimated $607K.
Hutchin Hill Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 7 quarters.
Hutchin Hill Capital's Impax Laboratories, Inc. position peaked at $1.25M in Q2 2016.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.